Literature DB >> 35422940

Mediator complex subunit 8 is a prognostic biomarker in hepatocellular carcinoma.

Shuang Wu1, Qiao Li1, Yuan Cao2, Senyuan Luo3, Zengguo Wang1, Taoyuan Zhang4.   

Abstract

BACKGROUND: Mediator complex subunit 8 (MED8) is known for its role in encoding a subunit of the mediator complex (MED), that is critical for transcription. MED8 is significantly expressed in various tumors and has been correlated with an unfavorable prognosis. Nevertheless, no relationships have been found between MED8 and the clinical characteristics of hepatocellular carcinoma (HCC).
METHODS: To conduct an evaluation of correlations between clinicopathologic characteristics and MED8 expression, the logistic regression, Wilcoxon signed-rank test, and Kruskal-Wallis test were used. To perform analysis of factors contributing to prognosis, the Kaplan-Meier approach and the Cox regression analyses were used. A nomogram on the basis of a Cox multivariate analysis was employed to anticipate the influence of MED8 on patient prognosis. The receiver operating characteristic (ROC) curves were plotted and the areas under the curve (AUC) were calculated to assess the prognostic value of MED8. Both immune infiltration analysis and Gene Set Enrichment Analysis (GSEA) were applied to reveal significant enrichment differences among TCGA data. Quantitative RT-PCR (qRT-PCR) and western blotting were used to verify the difference in the expression of MED8 in normal and hepatocellular carcinoma cells. The immunohistochemical method was used to validate the MED8 expression in tumor and adjoining tissues of HCC patients.
RESULTS: A univariate analysis showed that high MED8 expression predicts poor disease-specific survival (DSS) (HR: 2.57; 95% confidence interval (CI) 1.62, 4.07; P<0.001). Multivariate regression analysis showed that high MED8 (adjusted HR: 3.032 (1.817, 5.060); P<0.001) expression and M stage (adjusted HR=4.075 (1.179-14.091) for M1 vs. M0, P=0.026) served as prognostic indicators of unfavorable overall survival in an independent manner in patients with HCC. The C-index for the nomogram was 0.732 (95% CI: 0.698, 0.766) and the AUC of MED8 was 0.817 (95% CI: 0.778, 0.857). Functional analysis showed that the cell cycle checkpoints, p53 dependent G1-DNA damage response, mitotic G1-G1-S phases, and mitotic G2-G2-M phases, were significantly enriched in DEGs associated with MED8 expression. Th2 cells were positively correlated with MED8 expression.
CONCLUSIONS: MED8 predicts poor prognosis in HCC, possibly through modulating the cell cycle and Th2 cells. AJTR
Copyright © 2022.

Entities:  

Keywords:  Mediator complex subunit 8; diagnostic biomarker; hepatocellular carcinoma; mediator; prognosis

Year:  2022        PMID: 35422940      PMCID: PMC8991165     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  24 in total

Review 1.  Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Authors:  Virginia Hernandez-Gea; Sara Toffanin; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-09       Impact factor: 22.682

Review 2.  The mediator complex in genomic and non-genomic signaling in cancer.

Authors:  Hannah Weber; Michael J Garabedian
Journal:  Steroids       Date:  2017-11-21       Impact factor: 2.668

3.  MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.

Authors:  Sidong Huang; Michael Hölzel; Theo Knijnenburg; Andreas Schlicker; Paul Roepman; Ultan McDermott; Mathew Garnett; Wipawadee Grernrum; Chong Sun; Anirudh Prahallad; Floris H Groenendijk; Lorenza Mittempergher; Wouter Nijkamp; Jacques Neefjes; Ramon Salazar; Peter Ten Dijke; Hidetaka Uramoto; Fumihiro Tanaka; Roderick L Beijersbergen; Lodewyk F A Wessels; René Bernards
Journal:  Cell       Date:  2012-11-21       Impact factor: 41.582

Review 4.  Epidemiology and surveillance for hepatocellular carcinoma: New trends.

Authors:  Amit G Singal; Pietro Lampertico; Pierre Nahon
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

Review 5.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

6.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.

Authors:  Michael I Love; Wolfgang Huber; Simon Anders
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

7.  Comprehensive analysis of the transcriptional profile of the Mediator complex across human cancer types.

Authors:  Isabella Syring; Niklas Klümper; Anne Offermann; Martin Braun; Mario Deng; Diana Boehm; Angela Queisser; Anne von Mässenhausen; Johannes Brägelmann; Wenzel Vogel; Doris Schmidt; Michael Majores; Anne Schindler; Glen Kristiansen; Stefan C Müller; Jörg Ellinger; David Adler; Sven Perner
Journal:  Oncotarget       Date:  2016-04-26

8.  The immune contexture of hepatocellular carcinoma predicts clinical outcome.

Authors:  Friedrich Foerster; Moritz Hess; Aslihan Gerhold-Ay; Jens Uwe Marquardt; Diana Becker; Peter Robert Galle; Detlef Schuppan; Harald Binder; Ernesto Bockamp
Journal:  Sci Rep       Date:  2018-03-29       Impact factor: 4.379

9.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.

Authors:  Jianfang Liu; Tara Lichtenberg; Katherine A Hoadley; Laila M Poisson; Alexander J Lazar; Andrew D Cherniack; Albert J Kovatich; Christopher C Benz; Douglas A Levine; Adrian V Lee; Larsson Omberg; Denise M Wolf; Craig D Shriver; Vesteinn Thorsson; Hai Hu
Journal:  Cell       Date:  2018-04-05       Impact factor: 41.582

10.  Mediator MED23 regulates inflammatory responses and liver fibrosis.

Authors:  Zhichao Wang; Dan Cao; Chonghui Li; Lihua Min; Gang Wang
Journal:  PLoS Biol       Date:  2019-12-05       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.